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Value of clinical, ultrasonographic 
and MRI signs as diagnostic 
differentiators of non‑benign 
lipomatous tumours
Karishma Khan1,2, Elayne Azzopardi1*, Liberato Camilleri 4, Ernest A. Azzopardi1,3,4,5,5 & 
Thomas H. Bragg1,5,5
Suspicion of malignant change within a lipoma is a common and increasing workload within the 
UK Sarcoma multidisciplinary team (MDT) network, and a source of considerable patient anxiety. 
Currently, there is no lipoma‑specific data, with regard to which clinical or radiographic features 
predict non‑benign histology, or calculate an odds‑ratio specific to a lipomatous lesion being non‑
benign. We performed a 9‑year, double‑blind, unmatched cohort study, comparing post‑operative 
histology outcomes (benign versus non‑benign) versus 15 signs across three domains: Clinical (size of 
tumour, depth, growth noticed by patient, previous lipoma, patient felt pain), Ultrasonographic (size, 
depth, vascularity, heterogenous features, septae) and MRI (size, depth, vascularity, heterogenous 
features, septae, complete fat signal suppression). Receiver operating characteristic (ROC) analysis, 
odds ratios and binary logistic regression analysis was performed double‑blind. When each sign is 
considered independently, (ROC analysis, followed by binary logistic regression) only Ultrasound 
depth is a significant predictor (p = 0.044) of a histologically non‑benign lipoma. Ultrasonographically 
determined vascularity and septation were not statistically significant predictors. None of the 
clinical signs were statistically significant (p > 0.05). Of the MRI signs none was statistically significant 
(p > 0.05). However, heterogeneous MRI features fared better than MRI depth. Ultrasound signs 
(Pseudo R‑Square = 0.105) are more predictive of the post‑operation histology outcome than Clinical 
signs (Pseudo R‑Square = 0.082) or MRI tests (Pseudo R‑Square = 0.052) Ultrasound and Clinical tests 
combined (Pseudo R‑Square = 0.147) are more predictive of the post‑operation histology outcome 
than MRI tests (Pseudo R‑Square = 0.052). This work challenges the traditional perception of “red‑
flag” signs when applied to lipomatous tumours. We provide accurate data upon which an informed 
choice can be made, and provides a robust bases for expedited risk/benefit. The importance of an 
experienced and cohesive MDT network is emphasised.
Tumors of adipose represent both the commonest (50%) of all benign mesenchymal tumours as lipomas, and the 
commonest group of malignant mesenchymal neoplasms (liposarcomas), which incurs a considerable disease 
burden and healthcare  cost1,2. It is therefore surprising that there is no literature that explores the value of clini-
cal, ultrasonoraphic, and magnetic resonance imaging signs in current clinical use, alone or in combination, 
specifically in differentiating benign from non-benign adipose tumours.
The UK National Institute for Health and Care Excellence (NICE) recognises the difficulty in distinguishing 
benign from malignant tumours as the principal problem in their  management3. Discerning benign from malgi-
nant is the key decision that impacts on morbidity, mortality, and service  delivery4. Besides ultrasonograpy and 
magnetic resonance imaging, current consensus opinion both by NICE and the British Sarcoma Group advocates 
any lump with any size, or size > 5 cm, or deep to the deep fascia, or painful is considered higher risk for potential 
malignancy until proven otherwise, as a blanket approach to any soft tissue  sarcoma5,6.
OPEN
1The Welsh Centre for Burns and Plastic Surgery, Heol Maes Eglwys, Swansea SA66NL, UK. 2Cardiff University 
Medical School, Heath Park, Cardiff CF14 4XY, UK. 3University College London, London, UK. 4University of Malta 
Tal-Qroqq Campus, Malta GC. EU, UK. 5These authors jointly supervised this work: Ernest A. Azzopardi and Thomas 
H. Bragg. *email: Laser.surgeon@yahoo.com
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:20756  | https://doi.org/10.1038/s41598-020-77244-2
www.nature.com/scientificreports/
Study aims. To determine the diagnostic value of 15 signs across three domains, as used in standard sar-
coma multidisciplinary team (MDT) practice, for primary tumours of adipose: Clinical (size of tumour, depth, 
growth noticed by patient, previous lipoma, new onset of pain), Ultrasonographic (size, depth, vascularity, het-
erogenous features septae) and MRI (size, depth, vascularity, heterogenous features, septae, complete fat signal 
suppression).
Hypothesis That current clinical, ultrasonographic and magnetic resonance signs do not equally predict and 
differentiate benign from non-benign lipomatous tumours.
Operational definitions. We adopted A pragmatic, benign versus non-benign, binary approach, in keep-
ing with World Health Organisatiion (WHO)  defnitions7.
Gold standard was determined as the post-operative laboratory report histopathology, subject to standard UK 
National Health Service quality control criteria, and reported by an experienced validated MDT histopathologist.
“Benign” was defined as a lipoma, confirmed as benign on histologic report. “Non-benign” was determined 
as liposarcoma, including atypical lipomatous tumour/well-differentiated liposarcoma (which includes the adi-
pocytic, sclerosing, inflammatory and spindle cell variants); de-differentiated liposarcoma; myxoid liposarcoma; 
and pleomorphic  liposarcoma7.
Red flag Signs: The classical red flag signs were taken as defined by the National Institute for Health and Care 
Excellence (3, 5). These are reproduced in scheme 1.
Scheme 1. Features suggestive of malignancy in a lump.
• Lump > 5 cm
• Lump increasing in size
• Lump deep to the fascia
• Pain.
Inclusion criteria. Patients with both histology, ultrasonographic or magnetic imaging reporting, present-
ing with suspected non-syndromic tumours of adipose, operated within the Wales Sarcoma Service between 
2010 and March 2018.
Blinding. Data was anonymised at source. Data coding and primary analysis was performed blind. Statistical 
analysis was performed blind by an independent bio-statistician.
Ethics. This study was performed using retrospective anlysis of audit data anonymised at source. This was 
confirmed using the UK Health Research Authority’s online decisional analysis tool, and seconded by institu-
tional board  correspondence8,9. All analysis methods were carried out in accordance with governing institutional 
guidelines and regulations at Swansea University and affiliated  hospitals10 (clinical audit/service evaluation data).
Methods
We performed a 9-year, single sarcoma network, double-blind, unmatched cohort study, comparing post-oper-
ative histology outcomes (benign versus non-benign) versus 15 signs across three domains: Clinical (size of 
tumour, depth, growth noticed by patient, previous lipoma, patient felt pain), Ultrasonographic (size, depth, 
vascularity, heterogenous features septae) and MRI (size, depth, vascularity, heterogenous features, septae, com-
plete fat signal suppression). The data was collected from the Welsh Sarcoma Service and incorporates the work 
of a senior, validated MDT team working according to British Sarcoma Standards. Data coding was performed 
as per Supplementary  material1.
For each parameter, sensitivity, specificity, positive predictive value, negative predictive value, was followed 
by Reported-Observer Curve (ROC) analysis. Binary Logistic Regression Analysis was then used to investigate 
the collective contribution of signs in each domain area. Odds ratios were then calculated. Statistical significance 
was considered at p < 0.05. Data analysis was performed with SpSS for Windows (IBM Corp. Released 2017. 
Version 25.0. Armonk, NY: IBM Corp).
Results
Of 178 patients originally fulfilling inclusion criteria, histopathology reports were available in 106. Of these 
25 lacked either ultrasonographic or magnetic resonance imaging data and were excluded, and the remainder 
(81) were included in the study (Fig. 1). To our knowledge this is the largest reported cohort of patients in the 
Literature to date.
For each domain, sensitivity, specificity, positive predictive value, and negative predictive value are reported 
in Table 1.
Clinical domain. Size of lipoma. ROC analysis shows this has some predictive power. However, p-value 
(0.516) exceeds the 0.05 level of significance. This is mainly attributed to the fact that the number of false posi-
tives (55) is quite large.
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Depth of lipoma. The area under the ROC curve (0.600) exceeds the area under the 45-degree line (0.5) indicat-
ing that the depth of tumour has some predictive power. However, the p-value (0.255) exceeds the 0.05 level of 
significance indicating that this area is not significantly larger than 0.5. This is mainly attributed to the fact that 
the number of false positives (23) is quite large.
Growth noted by patient. The area under the ROC curve (0.391) is less than the area under the 45-degree line 
(0.5) indicating that growth noticed by patients has no predictive power. This is mainly attributed to the fact that 
the number of false negatives (8) and false positives (41) are larger than the true positives (5) and true negatives 
(27).
Previous lipoma. The area under the ROC curve (0.533) exceeds the area under the 45-degree line (0.5) indi-
cating that previous lipoma has some predictive power. However, the p-value (0.709) exceeds the 0.05 level of 
significance indicating that this area is not significantly larger than 0.5. This is mainly attributed to the fact that 
the number of false negatives (11) is quite large.
178 Paents (non-syndromic lipomatous 
lesions 2010-Jan 2018)
102 paents: Dataset complete72 paents Data set incomplete
25 paents: Incomplete Dataset 85 paents: Complete dataset
Nil post-data collecon exclusion Proceed to analysis
Figure 1.  Attrition diagram to suppport exlusion of patients.
Table 1.  Sensitivty, specificity, positive and negative predictive value for each parameter individually. 
Sens: sensitivity; spec: specificty; PpV: Postive predictive value; NpV: negative predictive value; heterog: 
heterogenous.
Parameter Sens (%) Spec (%) Ppv (%) Npv (%)
Clinical
Size > 5 cm 92.3 19.1 17.9 92.8
Depth 53.85 66.18 23.33 88.24
Growth 38.46 39.71 10.87 77.14
Pain 23.08 73.53 14.29 83.33
Previous lipoma 15.38 91.18 25.00 84.93
Ultrasonographic
Size > 5 cm 61.54 31.34 14.81 80.77
Depth 46.15 75.76 27.27 87.72
Vascularity 33.33 77.61 21.05 86.67
Heterog. features 7.69 92.54 16.67 83.73
Septation 15.38 94.03 33.33 85.14
MRI
Size > 5 cm 66.67 9.76 13.95 57.14
Depth 55.56 56.10 21.74 85.19
Vascularity 0 85.36 0 79.55
Heterog features 33.33 82.93 30.00 v85.00
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Pain. The area under the ROC curve (0.483) is less than the area under the 45-degree line (0.5) indicating that 
the pain felt by patients has no predictive power. This is mainly attributed to the fact that the number of false 
negatives (10) is larger than the number of true positives (3).
Although none of three predictors are significant, depth of tumour is the better of the three, followed by size of 
tumour and previous Lipoma. When the above three parameters we investigated collectively as potential predic-
tors using a binary logistic regression model, the parameters explain only 8.2% of the post-operation histology 
outcome. The Odds ratios are reported in Table 2.
Ultrasound domains. Ultrasonographic size: The area under the ROC curve (0.464) is less than the area 
under the 45-degree line (0.5) indicating that size of ultrasound has no predictive power. This is mainly attrib-
uted to the fact that the number of false positives (46) is large.
Ultrasonographic depth: The area under the ROC curve (0.610) exceeds the area under the 45-degree line (0.5) 
indicating that tumours occuring adjacent to or deep to fascia has some predictive power. However, the p-value 
(0.214) exceeds the 0.05 level of significance indicating that this area is not significantly larger than 0.5. This is 
mainly attributed to the fact that the number of false positives (16) is quite large.
Ultrasonographic evidence of tumour vascularity: the area under the ROC curve (0.555) exceeds the area 
under the 45-degree line (0.5) indicating that the ultrasound vascularity has some predictive power. However, 
the p-value (0.548) exceeds the 0.05 level of significance indicating that this area is not significantly larger than 
0.5. This is mainly attributed to the fact that the number of false positives (15) is quite large.
Ultrasonographic evidence of tumour heterogeneity: The area under the ROC curve (0.501) exceeds the area 
under the 45-degree line (0.5) by a very small margin indicating that the ultrasound heterogeneous feature has 
very little predictive power. Moreover, the p-value (0.990) exceeds the 0.05 level of significance indicating that 
this area is not significantly larger than 0.5. This is mainly attributed to the fact that the number of false nega-
tives (12) is quite large.
Ultrasound detection of septae: The area under the ROC curve (0.547) exceeds the area under the 45-degree 
line (0.5) indicating that the ultrasound detected septae has some predictive power. However, the p-value (0.593) 
exceeds the 0.05 level of significance indicating that this area is not significantly larger than 0.5. This is mainly 
attributed to the fact that the number of false negatives (11) is quite large.
Binary logistic regression of ultrasonographic domains. Logistic regression analysis was used to 
investigate the collective contribution of Ultrasound depth, ultrasound detected vascularity and ultrasound 
septae in predicting the outcome (non-benign, benign) of the post-operation histology. This three-predic-
tor logistic regression model explains 10.5% of the post-operation histology outcome (Nagelkerke Pseudo 
R-Square = 0.105).  Moreover,  ultrasound  tumour depth is a significant predictor (p = 0.044). Consequently it 
appears that ultrasound depth is the better of the three, followed by ultrasonographic evidence of vascularity 
and tumour septation.
The odds ratios, displayed in Table 3, all indicate that tumours of size 5 cm or more, tumours which abuts 
fascia or are deep to fascia and previous lipoma in the same position increase the risk that the post-operation 
histology yields a non-benign tumour since these odds are all larger than 1. However, these odds ratios are not 
significantly larger than 1 because the p-values exceed the 0.05 level of significance.
Table 2.  Odds of a non-benign histology for each clinical sign evaluated.
Parameter Odds ratio
lump > 5 cm If size of tumour is 5 cm or more, the odds that post-operation histology yields a non-benign tumour is 3.633 times when size of tumour is less than 5 cm
Tethered to fascia or deeper structures If the tumour includes fascia or is deep to fascia, the odds that post-operation histology yields a non-benign tumour is 2.257 times when tumour depth is superficial
Previous lipoma If previous lipoma is in the same position, the odds that post-operation histology yields a non-benign tumour is 3.341 times when no previous lipomas are reported
Table 3.  Odds of a non-benign histology for each clinical sign evaluated.
Parameter Odds ratio
Ultrasound tumour depth If ultrasound tumour depth is fascial or sub-fascial, the odds that post-operation histology yields a non-benign tumour is 4.059 times when ultrasound depth is superficial
Vascularity If the tumour displays vascularity, the odds that post-operation histology yields a non-benign tumour is 2.471 times when tumour does not invade microvasculature
Septation If ultrasound detected septae are present, the odds that post-operation histology yields a non-benign tumour is 1.394 times when septae are not present
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MRI results. Size: The area under the ROC curve (0.382) is less than the area under the 45-degree line (0.5) 
indicating that MRI size has no predictive power. This is mainly attributed to the fact that the number of false 
positives (37) is large.
Depth: The area under the ROC curve (0.558) exceeds the area under the 45-degree line (0.5) indicating 
that the MRI depth has some predictive power. However, the p-value (0.587) exceeds the 0.05 level of signifi-
cance indicating that this area is not significantly larger than 0.5. This is mainly attributed to the fact that the 
number of false positives (18) is quite large.
MRI detected vascularity: The area under the ROC curve (0.427) is less than the area under the 45-degree 
line (0.5) indicating that MRI detected tumour vascularity has no predictive power. This is mainly attributed to 
the fact that the number of false negatives (9) is large.
MRI heterogenous features: The area under the ROC curve (0.581) exceeds the area under the 45-degree 
line (0.5) indicating that the MRI evidence of heterogeneous features have some predictive power. However, the 
p-value (0.449) exceeds the 0.05 level of significance indicating that this area is not significantly larger than 0.5). 
This is mainly attributed to the fact that the number of false negatives (6) is quite large.
MRI Septae: The area under the ROC curve (0.409) is less than the area under the 45-degree line (0.5) indicat-
ing that MRI evidence of septation has no predictive power. This is mainly attributed to the fact that the number 
of false negatives (8) is large.
MRI fat suppression: The area under the ROC curve (0.336) is less than the area under the 45-degree line 
(0.5) indicating that Fat completely suppressed has no predictive power. This is mainly attributed to the fact that 
the number of false negatives (8) and false positives (18) are large.
Logistic regression for MRI criteria. Logistic regression analysis was used to investigate the collective con-
tribution of MRI depth and MRI heterogeneous features in predicting the outcome (non-benign, benign) of 
the post-operation histology. This two-predictor logistic regression model explains 5.2% of the post-operation 
histology outcome (Nagelkerke Pseudo R-Square = 0.052). Although none of these two predictors are significant, 
MRI heterogeneous features is the better of the two, followed by MRI depth.
Table 4 displays the odds ratios. The odds ratios all indicate that tumours that involve fascia or invades to 
fascia on MRI and heterogeneous features on MRI increase the risk that the post-operation histology yields a 
non-benign tumour since these odds are all larger than 1. However, these odds ratios are not significantly larger 
than 1 because the p-values exceed the 0.05 level of significance.
Additionally, we used logistic regression analysis was used to investigate the collective contribution of size of 
tumour, depth of tumour, previous Lipoma, ultrasound depth, ultrasound tumour vascularity and ultrasound 
septae in predicting the outcome (non-benign, benign) of the post-operation histology. Now, this six-predictor 
logistic regression model now explains 14.7% of the post-operation histology outcome (Nagelkerke Pseudo 
R-Square = 0.147).
Result summary
Of the clinical tests, depth of tumour is the best predictor of the post-operation histology outcome (non-benign, benign), followed by size 
of tumour and previous lipoma
Of the ultrasound tests, ultrasound depth is the best predictor of the post-operation histology outcome (non-benign, benign), followed by 
ultrasound tumour vascularity and ultrasound septae. Depth is also statistically significant on ROC analysis
Of the MRI tests, heterogeneous features on MRI is the best predictor of the post-operation histology outcome (non-benign, benign), fol-
lowed by MRI depth
Of the clinical and ultrasound tests combined, ultrasound depth is the best predictor of the post-operation histology outcome (non-benign, 
benign), followed by size of tumour, ultrasound vascularity and previous lipoma
Ultrasound tests (Pseudo R-Square = 0.105) are more predictive of the post-operation histology outcome than Clinical tests (Pseudo 
R-Square = 0.082) and MRI tests (Pseudo R-Square = 0.052)
Ultrasound and Clinical tests combined (Pseudo R-Square = 0.147) are more predictive of the post-operation histology outcome than MRI 
tests (Pseudo R-Square = 0.052)
Discussion
The decision when to operate can be difficult with regard to tumours of adipose. An important aim in sarcoma 
management is early diagnosis and prompt  referral11. Our study shows that the classical “red-flag”  signs5 that are 
associated with malignant change are of limited value in the differentiation of lipomatous tumours. Much of the 
bases for the current “red flag symptoms” is based on the work of Johnson Pysent and  Grimer12. These authors 
used a weighting scheme to measure the likelihood of a malignant lesion and then converted this weight to a 
probability using the logistic function, where larger weights corresponded to higher probabilities of malignant 
Table 4.  Odds of a non-benign histology for each clinical sign evaluated.
Parameter Odds ratio
MRI depth If MRI depth involves fascia or reaches deep to fascia, the odds that post-operation histology yields a non-benign tumour is 1.708 times when MRI depth is superficial to fascia
MRI features are heterogeneous If MRI features are heterogeneous, the odds that post-operation histology yields a non-benign tumour is 2.557 times when MRI features are homogeneous
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lesions. Our work differs in serveral ways. Firstly, our approach is model-based where the contribution of each 
parameter is investigated individually using ROC curve analyses and then collectively with other parameters 
using Binary Logistic models. These models, which are appropriate for analyzing binary responses, yield odds 
ratios which measure the likelihood of non-benign histology in the presence of a parameter when compared 
to its absence. Moreover, we only included lipomatous tumours and data retrieval was double cross-checked. 
Statistical analysis was performed blind by an experienced statistician.
Only ultrasonographically determined tumour depth withstood binary logistic regression analysis to emerge 
as a significant predictor of the post-operative histology. Further, our results show that combined ultrasono-
graphic and clinical examination, may be more predictive of post-operative histology when compared to mag-
netic resonance imaging in isolation. These results may also have implications on service delivery, access and 
co-production decision sharing. Patient anxiety and reduced quality of life often accompany the interim period 
between referral and final diagnosis. The odds ratios presented herein for each sign, contribute to informing 
decisions taken jointly between patient and the clinical team, and clarifying informed consent. In the presence of 
conflicting clinical, or radiological evidenced, these findings may facilitate MDT co-production decision making 
based upon the predictive strength of the individual signs within each domain. Further, the predictive superiority 
of combined clinical plus ultrasonographic examination, in particularly depth on ultrasound, have implications 
for service delivery and access. The Welsh Sarcoma Service now offers combined sarcoma screening clinics which 
are both rapid access and cost-saving compared to MRI imaging. Whilst the latter retains an important role in 
diagnostics, its use may be more focused on surgical planning and possible morbidity from surgery.
Limitations and direction of future research: Our findings are dependent on a caveat of a highly experienced 
sarcoma MDT being inolved in clinical examination. We also noted that some of the main effects (ultrasound 
depth, size of tumour, ultrasound vascularity and previous lipoma) yielded p-values that exceeded the 0.05 
level of significance by a small margin. Even though, to our knowledge, this was the study with the largest study 
sample size reported in the literature to date, we cannot exlcude the possibility that these predictors could be 
significant if the sample size had to be increased further. It is known that when conducting hypothesis testing, 
the p-value depends heavily on the sample size and it is very unlikely to attain statistical significance in the pres-
ence of heterogeneous responses.
These findings and their implications have been incorporated in the Welsh Sarcoma Service Multidisicplinary 
Meeting policy and form the bases our current practice.
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